CN114466853B - 抗癌化合物及其医药用途 - Google Patents

抗癌化合物及其医药用途

Info

Publication number
CN114466853B
CN114466853B CN202080067311.3A CN202080067311A CN114466853B CN 114466853 B CN114466853 B CN 114466853B CN 202080067311 A CN202080067311 A CN 202080067311A CN 114466853 B CN114466853 B CN 114466853B
Authority
CN
China
Prior art keywords
cancer
compound
mmol
tumor
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080067311.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN114466853A (zh
Inventor
李安蓉
段建新
孟繁英
蔡晓宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Ascentawits Pharmaceutical Technology Co ltd
Original Assignee
Shenzhen Ascentawits Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Ascentawits Pharmaceutical Technology Co ltd filed Critical Shenzhen Ascentawits Pharmaceutical Technology Co ltd
Publication of CN114466853A publication Critical patent/CN114466853A/zh
Application granted granted Critical
Publication of CN114466853B publication Critical patent/CN114466853B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/564—Three-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN202080067311.3A 2019-12-20 2020-09-10 抗癌化合物及其医药用途 Active CN114466853B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911324466 2019-12-20
CN2019113244666 2019-12-20
PCT/CN2020/114519 WO2021120717A1 (zh) 2019-12-20 2020-09-10 抗癌化合物及其医药用途

Publications (2)

Publication Number Publication Date
CN114466853A CN114466853A (zh) 2022-05-10
CN114466853B true CN114466853B (zh) 2026-04-14

Family

ID=76477075

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080067311.3A Active CN114466853B (zh) 2019-12-20 2020-09-10 抗癌化合物及其医药用途
CN202180036541.8A Pending CN115667278A (zh) 2019-12-20 2021-06-23 乏氧活化的dna烷化剂及其医药用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180036541.8A Pending CN115667278A (zh) 2019-12-20 2021-06-23 乏氧活化的dna烷化剂及其医药用途

Country Status (7)

Country Link
US (2) US20230026163A1 (cg-RX-API-DMAC7.html)
EP (2) EP4079738A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023542286A (cg-RX-API-DMAC7.html)
KR (1) KR20230065309A (cg-RX-API-DMAC7.html)
CN (2) CN114466853B (cg-RX-API-DMAC7.html)
TW (4) TWI837402B (cg-RX-API-DMAC7.html)
WO (2) WO2021120717A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI837402B (zh) * 2019-12-20 2024-04-01 大陸商深圳艾欣達偉醫藥科技有限公司 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
EP4428138A4 (en) * 2021-11-05 2025-08-27 Ascentawits Pharmaceuticals Ltd AKR1C3-ACTIVATED DNA ALKYLATING AGENT AND ITS MEDICAL USE
CN116120365A (zh) 2021-11-12 2023-05-16 深圳艾欣达伟医药科技有限公司 一种氘代化合物及其制备方法和应用
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
EP4529926A4 (en) 2022-05-23 2026-07-01 Ascentawits Pharmaceuticals Ltd CANCER TREATMENT METHOD BY COMBINATION OF AN ALKYLATING AGENT PRODRUGATION AND A CELL CYCLE INHIBITOR
CN115626938B (zh) * 2022-09-02 2026-04-17 温州医科大学 一种化合物rx4及其在抗结肠癌药物中的作用
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
CN121175032A (zh) * 2023-05-11 2025-12-19 深圳艾欣达伟医药科技有限公司 一种注射液制剂、配伍药液及其制备方法
EP4755396A1 (en) 2023-07-28 2026-06-10 Ascentawits Pharmaceuticals, Ltd. Treatment of p53 gene mutation or defect negative cancer and tumor patients
CN121985960A (zh) 2023-10-18 2026-05-05 深圳艾欣达伟医药科技有限公司 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108024974A (zh) * 2015-06-24 2018-05-11 分子模板公司 含有dna烷化剂的氮丙啶

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617398A (en) * 1982-04-12 1986-10-14 The Research Foundation Of State University Of New York Phosphoaziridine compounds useful for treatment of tumors
AU5935600A (en) * 1999-07-14 2001-01-30 Richard F. Borch Phosphoramide compounds
WO2004062596A2 (en) * 2003-01-09 2004-07-29 Zeneus Pharma Limited Antineoplastic ether lipid compounds having a four carbon backbone
CA2592116A1 (en) * 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
CA2592118C (en) * 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
CN1948311A (zh) * 2006-11-09 2007-04-18 上海交通大学 2－碘代苯基－6－三氟甲基咪唑并[1,2－a]吡啶－3－乙酰胺类化合物及制备方法
US9278904B2 (en) * 2013-12-31 2016-03-08 Chemapotheca, Llc Synthesis of chiral amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds
CN104098432B (zh) * 2014-06-30 2016-03-30 福建师范大学福清分校 一种三氟甲基化芳烃的合成方法
WO2016145092A1 (en) * 2015-03-10 2016-09-15 Threshold Pharmaceuticals, Inc. Dna alkylating agents
KR101985778B1 (ko) * 2015-11-16 2019-06-04 아센타위츠 파마슈티컬즈 리미티드 (r)- 및 (s)-1-(3-(3-n,n-다이메틸아미노카보닐)페녹시-4-나이트로페닐)-1-에틸-n,n'-비스(에틸렌)포스포르아미데이트, 조성물 및 이의 사용 방법 및 제조
CN106279321A (zh) 2016-08-09 2017-01-04 南京医科大学 吉西他滨ProTide乏氧活化前药及其应用
CN107118231B (zh) * 2017-03-17 2019-06-07 北京大学 萘醌磷酰胺类化合物及其在作为细胞铁死亡诱导剂中的用途
WO2018184003A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
CN107513057A (zh) 2017-09-06 2017-12-26 南京医科大学 一类乐伐替尼的乏氧活化前药及其应用
TW201919644A (zh) * 2017-09-29 2019-06-01 台灣浩鼎生技股份有限公司 治療血癌的方法
WO2020022868A1 (ko) * 2018-07-27 2020-01-30 에스케이이노베이션 주식회사 입자 균일도가 우수한 모데나이트 제올라이트 및 그 제조방법
TWI837402B (zh) * 2019-12-20 2024-04-01 大陸商深圳艾欣達偉醫藥科技有限公司 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108024974A (zh) * 2015-06-24 2018-05-11 分子模板公司 含有dna烷化剂的氮丙啶

Also Published As

Publication number Publication date
US20230026163A1 (en) 2023-01-26
TW202128188A (zh) 2021-08-01
US20230339991A1 (en) 2023-10-26
EP4079738A1 (en) 2022-10-26
CN115667278A (zh) 2023-01-31
CN114466853A (zh) 2022-05-10
TWI833055B (zh) 2024-02-21
KR20230065309A (ko) 2023-05-11
EP4079738A4 (en) 2024-04-24
JP2023542286A (ja) 2023-10-06
TWI837402B (zh) 2024-04-01
EP4212538A1 (en) 2023-07-19
TWI893202B (zh) 2025-08-11
WO2021120717A1 (zh) 2021-06-24
EP4212538A4 (en) 2024-11-13
TW202135831A (zh) 2021-10-01
TW202421161A (zh) 2024-06-01
WO2022052564A1 (zh) 2022-03-17
TW202210083A (zh) 2022-03-16

Similar Documents

Publication Publication Date Title
TWI833055B (zh) 抗癌化合物及其醫藥用途
Liu et al. Hybridization-based discovery of novel quinazoline-2-indolinone derivatives as potent and selective PI3Kα inhibitors
EP3385262B1 (en) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-amine derivatives as protein kinase inhibitors, preparation method and medical use thereof
JP5694172B2 (ja) カルバゾール化合物および当該化合物の治療用途
JP2020536847A (ja) プログラマブルなポリマー薬物
JP2021502388A (ja) Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法
CA3085759A1 (en) Hsp90-targeting conjugates and formulations thereof
WO2022199547A1 (zh) 一种7,9-二氢嘌呤衍生物及其制药用途
JP2021523168A (ja) がん幹細胞を標的化するがん治療
You et al. Design, synthesis and biological evaluation of N-arylsulfonyl carbazoles as novel anticancer agents
CN118201940A (zh) Akr1c3活化的dna烷化剂及其医药用途
CN119019391A (zh) 一类氮杂喹诺酮化合物的合成方法及其用途
JP2021527064A (ja) Ｐｒｃ１阻害剤及びそれを用いた治療方法
Wang et al. Discovery of a tribenzophenazine analog for binding to the KRAS mRNA G-quadruplex structures in the cisplatin-resistant non–small cell lung cancer
WO2024211314A2 (en) Inhibitors of chd1l and uses thereof
Wang et al. Mitochondria-targeting artesunate-rhein conjugates: Linker-modulated cell-permeability, heme-affinity and anticancer activity
Wang et al. Design and Synthesis of Novel Dual Fluoro-Substituted 10, 11-Methylenedioxy-pyrrolo [3, 4-b] quinoline Alkaloid Analogs as Topo I/DDX5 Inhibitors for Colorectal Cancer
Yuan et al. Pioneering 4, 11-Dioxo-4, 11-dihydro-1 H-anthra [2, 3-d] imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy
Babu et al. 9-Arylacenaphtho [1, 2-b] quinoxalines via Suzuki coupling reaction as cancer therapeutic and cellular imaging agents
Salerno et al. Benzothiopyranoindole-and pyridothiopyranoindole-based antiproliferative agents targeting topoisomerases
CN112279863A (zh) Hsp90抑制剂与喜树碱衍生物的偶联物及其制备方法与应用
CN116063328B (zh) 一种四环喹诺酮化合物、药学上可接受的盐及其应用
Yu et al. Design, Synthesis and Evaluation of a Novel Teoptinib Derivative as an Effective Anti-hepatocellular Carcinoma Agent
Mengting Synthesis of ALK Inhibitors and Analysis of Structure-activity Relationship
Gao Development of Prodrugs for the Targeted Delivery of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Cytotoxic Agents in Cancer Therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant